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BRIEF COMMUNICATION
HEPATITIS C VIRUS INFECTION IN HEMODIALYSIS PATIENTS IN MARACAIBO, VENEZUELA
Francisca MONSALVE-CASTILLO(1), Liliana GÓMEZ-GAMBOA(2), Leonor CHACÍN-BONILLA(3) Leticia PORTO-ESPINOZA(4) & Luciana COSTA-LEÓN(1)
SUMMARY
Over a two year period, the incidence of hepatitis C virus (HCV) infection was evaluated in 29 hemodialysis patients, aged between 
15 and 75 years (mean ± SD: 45 ± 39.5 years), from the University Hospital Hemodyalisis Unit, Maracaibo, Zulia State, Venezuela. 
Anti-HCV antibodies were determined using a fourth generation ELISA (Innotest HCV Ab IV) kit and positive blood samples were 
tested using a recombinant assay kit (Inno-LIA HCV Ab III), both kits from Innogenetics N.V., Belgium. The findings indicate a lack 
of HCV seroconversion in the hemodialysis patients over the study period, confirmed by the recombinant assay. Risk factors for HCV 
infection were 0.3270 (95% confidence interval: 0.01323-8.080) in patients undergoing hemodialysis. The findings suggest a lack of 
significant sources for HCV infection due to the preventive measures to avoid its transmission in the hemodialysis unit.
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It is generally accepted that the parenteral route is the main 
transmission mechanism for infection of hepatitis C virus (HCV). 
Risk factors for HCV infection include blood transfusion and blood 
products from non-tested blood donors; organ transplantation from 
infected donors, administration of drugs with contaminated syringes, 
hemodialysis, occupational exposure to blood, perinatal infection and 
sexual transmission2,4,13,14,18. Moreover, due to the great variety of human 
activities with potential exposure to blood, several possible biologic 
transmission models exist, such as from tattoos, piercings, barber shops, 
scarification rituals, circumcisions and acupuncture7.
Among the different risk factors, the most common include 
blood transfusion, intravenous drug use and invasive therapies with 
contaminated equipment2,4. However, a significant variation in the 
importance of each of those factors in disease transmission was observed 
over time in each region1. The transmission of HCV in hemodialysis units 
merits special attention since it can occur by several routes11,16. 
The prevalence of HCV infection in patients undergoing dialysis 
is greater than that in the general population, suggesting that patients 
on dialysis may be at higher risk of acquiring HCV infection. This is 
predominantly because these patients are more exposed to risk factors 
for the acquisition of this infection and also because they are monitored 
monthly by laboratory examinations that permit an early diagnosis 
of the infection19. The prevalence of HCV infection in hemodialysis 
patients can vary from 7% up to 70% in some countries11,16. Among 
the factors associated with higher HCV infection rates in hemodialysis 
patients are the time of dialysis and demographic region. Hepatitis C 
virus transmission among hemodialysis patients is mainly nosocomial. 
Possible risk factors include sharing hemodialysis equipment and 
instruments and the lack of adhesion to standard precaution measures 
and equipment sterilization7,11. More than 15 years ago, the prevalence 
of HCV infection among hemodialysis patients in Venezuela was 
between 25% and 71%3,12. However, in recent years, HCV infection 
in hemodialysis patients has not been observed and its prevalence in 
other populations is no higher than 1%, suggesting the low prevalence 
of anti-HCV in the country8-10. 
The aim of this study was to establish the incidence of HCV in a 
longitudinal study of patients undergoing hemodialysis in one unit of 
the University Hospital, Maracaibo, Zulia State, Venezuela. Over a two 
year period, 2007-2009, 29 patients aged between 15 and 75 years (mean 
± DS: 45 ± 39.5 years), who began dialysis treatment at the Maracaibo 
University Hospital were monitored. Baseline blood samples were taken 
at the start of dialysis treatment to rule out past infection. Subsequent 
samples were taken every three months.
The patients enrolled were required to have not received a blood 
transfusion during the study period and to be seronegative to HCV 
antibodies. Eight mL of venous blood was withdrawn from each patient 
before, during and after hemodialysis procedure. The samples were 
centrifuged to obtain the sera, which were refrigerated at -20 ºC until 
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processing. From the clinical records of the patients, data including 
medical history and risk factors for HCV were obtained. Consent from 
the patients was obtained before enrollment in the study. The ethical 
aspects of the study follow the principles outlined in the Declaration of 
Helsinki (October 2001). 
Anti-HCV antibodies were determined using a fourth generation 
enzyme-linked immunosorbent assay (ELISA) kit (Innotest HCV 
Ab IV from Innogenetics N.V., Belgium). The specificity of the anti-
HCV antibodies was evaluated using the third generation recombinant 
immunoblot kit (Innolia HCV Ab III, Innogenetics N.V.). The results were 
submitted for statistical analysis. The data are presented in frequency 
distribution tables and correlations among the variables examined were 
established by Pearson’s correlation analysis. The risk factors for HCV 
infection in patients undergoing hemodialysis were determined as 
indicated by FERNANDEZ et al. (1997)5. 
These results indicate a lack of anti-HCV antibodies and no HCV 
seroconversion was observed in the 29 patients on dialysis over the study 
period. The risk factors for HCV infection established for the dialysis 
patients were 1 to 3 blood transfusions before the study in 51.7%, 
several sexual partners in 24.1%, intravenous drugs in 3.4% and previous 
surgery in 38% (Table 1). Risk factors for acquiring HCV infection / 
HCV seroconversion were 0.3270 (95% CI: 0.01323, 8.080) for the 
hemodialysis patients. A limitation of the present work is that some of 
the patients with chronic renal disease using immunosuppressant drugs 
sometimes do not produce antibodies. 
These findings could be attributed to the preventive measures taken by 
the dialysis unit, including the recommended universal infection-control 
precautions, designed to control the spread of HCV. This dialysis unit 
is currently equipped with instruments that use disposable dialyzers. In 
between the two sessions, the machines are subjected to strict cleaning, 
disinfection and sterilization protocols. Patients who are seropositive 
for hepatitis B and C viruses and human immunodeficiency virus (HIV) 
infections at the beginning of treatment are assigned to a separate 
room with different machines and nursing personnel to those used for 
seronegative patients. 
The results obtained are quite different from those observed 
in previous years when the prevalence of HCV among patients on 
hemodialysis in Venezuela was as high as 71.3%12. Other authors6,17 who 
detected a low seroconversion rate in populations of dialyzed patients 
before preventive measures were adopted, concluded that prevention was 
the main factor for reducing anti-HCV seroconversion, particularly in 
units with an originally high prevalence. The low estimated incidence 
of 0.5% of new HCV infections/year obtained by SAUNÉ et al. (2011)15 
emphasizes the importance of adhering to the recommended universal 
infection-control precautions. 
The transmission of HCV is probably not associated with 
the dialysis procedure itself, but rather with a lack of knowledge 
regarding the application of preventative methods, including universal 
precautions. In conclusion, the low prevalence of HCV virus in the 
dialysis unit of the University Hospital of Maracaibo, suggests the lack 
of significant sources for nosocomial infections in this environment. 
In hemodialysis patients, it is likely that the preventive measures 
implemented in the dialysis unit have contributed to the control of the 
transmission of HCV infection. 
RESUMO
Infecção pelo vírus da Hepatite C em pacientes em hemodiálise em 
Maracaibo, Venezuela
Durante período de 2 anos, estudamos a incidência da infecção pelo 
vírus da hepatite C (VHC) em 29 pacientes em tratamento de diálise, 
com idades entre 15 e 75 anos (χ ± DS; 45 ± 39,5 anos), procedentes 
da unidade de hemodiálise do Hospital Universitário de Maracaibo, 
Estado Zulia, Venezuela. Para a detecção dos anticorpos contra o VHC 
(anti-VHC) utilizamos a técnica de imunoensaio enzimático (ELISA, 
Innotest HCV Ab IV) e em amostras reativas por ELISA, utilizamos 
o método de immunoblot recombinante de terceira geração (Inno-LIA 
HCV Ab III), ambos da casa comercial Innogenetics N.V., Bélgica. Os 
resultados demonstram ausência de soroconversão ao VHC nos pacientes 
hemodializados durante o período estudado, o que foi confirmado pelo 
método de imunoblot recombinante. Os fatores de risco ao VHC foram 
0,327 (95% CI: 0,01323 - 8,080) nos pacientes submetidos ao tratamento 
de diálise. Nossos resultados sugerem ausência de fontes de infecção 
neste centro de hemodiálise e que as medidas universais de controle de 
infecção são cumpridas. 
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Risk factors for hepatitis C virus infection in patients undergoing hemodialysis, 
2007-2009, in one of the dialysis units at the university hospital. Maracaibo, 
Venezuela
Risk factors No. (%)
Hemodialysis patients (29)
Transfusions
     No
     1-3
     4-9
     > 10
Number of sexual partners
     No/One
     Several
Use of injected drugs
     No
     Yes
Other medical procedures
     No
     Yes (Minor, and major surgeries)
7
15
5
2
22
7
28
1
18
11
24.1
51.7
17.2
6.9
75.8
24.1
96.5
3.4
62.0
38.0
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